Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 6/2012

Ausgabe 6/2012

Inhaltsverzeichnis ( 40 Artikel )

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012

(+)-Episesamin exerts anti-neoplastic effects in human hepatocellular carcinoma cell lines via suppression of nuclear factor-kappa B and inhibition of MMP-9

Christian Freise, Wolfram Trowitzsch-Kienast, Martin Ruehl, Ulrike Erben, Daniel Seehofer, Ki Young Kim, Martin Zeitz, Rajan Somasundaram

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012

Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients

Maria Cristina Villarroel, Keith W. Pratz, Linping Xu, John J. Wright, B. Douglas Smith, Michelle A. Rudek

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012 Open Access

Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells

Euphemia Leung, Gordon W. Rewcastle, Wayne R. Joseph, Rhonda J. Rosengren, Lesley Larsen, Bruce C. Baguley

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012

MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation

Li Wang, Kathy A. Mason, K. Kian Ang, Thomas Buchholz, David Valdecanas, Anjili Mathur, Carolyn Buser-Doepner, Carlo Toniatti, Luka Milas

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012

Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation

Kaouther Kolli-Bouhafs, Abdelaziz Boukhari, Abdurazzag Abusnina, Emilie Velot, Jean-Pierre Gies, Claire Lugnier, Philippe Rondé

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012

Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy

Thierry Marysael, Matthias Bauwens, Yicheng Ni, Guy Bormans, Jef Rozenski, Peter de Witte

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012

Using the neurotransmitter serotonin to target imaging agents to glioblastoma cells

Alexander Sturzu, Sumbla Sheikh, Uwe Klose, Hartmut Echner, Hubert Kalbacher, Martin Deeg, Thomas Nägele, Marius Horger, Ulrike Ernemann, Stefan Heckl

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012

The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines

Hyun-Jin Nam, Hwang-Phill Kim, Young-Kwang Yoon, Sang-Hyun Song, Ah-Rum Min, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, Yung-Jue Bang

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012

Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models

Sharon L. Longo, David J. Padalino, Sandra McGillis, Kirstin Petersen, Hartmut Schirok, Oliver Politz, Gregory W. Canute, Dawn E. Post

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012

Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy

Céline Clémenson, Cyrus Chargari, Laurent Désiré, Anne-Sophie Casagrande, Jean Bourhis, Eric Deutsch

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012

Quinones and halogenated monoterpenes of algal origin show anti-proliferative effects against breast cancer cells in vitro

Jo-Anne de la Mare, Jessica C. Lawson, Maynard T. Chiwakata, Denzil R. Beukes, Adrienne L. Edkins, Gregory L. Blatch

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012 Open Access

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

David A. Proia, Jim Sang, Suqin He, Donald L. Smith, Manuel Sequeira, Chaohua Zhang, Yuan Liu, Shuxia Ye, Dan Zhou, Ronald K. Blackman, Kevin P. Foley, Keizo Koya, Yumiko Wada

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012

Ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid inhibits hepatocellular carcinoma in vitro and in vivo via stabilizing IkBα

George G. Chen, Jackie Leung, Nian Ci Liang, Li Li, Kefeng Wu, Ursula P. F. Chan, Billy C. S. Leung, Mingyue Li, Jing Du, Yi Feng Deng, Xianling Gong, Yingnian Lv, Ernest C. W. Chak, Paul B. S. Lai

01.12.2012 | Ausgabe 6/2012

Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer

Chloe E. Atreya, Gregory S. Ducker, Morris E. Feldman, Emily K. Bergsland, Robert S. Warren, Kevan M. Shokat

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012 Open Access

Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas

Angela Ruban, Tamara Berkutzki, Itzik Cooper, Boaz Mohar, Vivian I. Teichberg

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012

Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression

Zarina J. D’Costa, Cheng-Mee Leong, Justin Shields, Charles Matthews, Merilyn H. Hibma

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012

Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling

Alfeu Zanotto-Filho, Elizandra Braganhol, Ana Maria Oliveira Battastini, José Cláudio Fonseca Moreira

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012

Screening candidate anticancer drugs for brain tumor chemotherapy: Pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues

Hua Lv, Fan Wang, M. V. Ramana Reddy, Qingyu Zhou, Xiaoping Zhang, E. Premkumar Reddy, James M. Gallo

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012

Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias

Patrick Ziegler, Tuhama Chahoud, Thomas Wilhelm, Nora Pällman, Melanie Braig, Valeska Wiehle, Susanne Ziegler, Marcus Schröder, Chris Meier, Adrian Kolodzik, Matthias Rarey, Jens Panse, Joachim Hauber, Stefan Balabanov, Tim H. Brümmendorf

01.12.2012 | PRECLINICAL STUDIES | Ausgabe 6/2012

Anti-leukemic effect of 2-pyrone derivatives via MAPK and PI3 kinase pathways

Jin Sun Yoon, Young Woong Won, Seo Ju Kim, Suk Joong Oh, Eun Shil Kim, Byoung Kook Kim, Cheon Gyu Cho, Jung Hye Choi, Byeong Bae Park, Min Ho Lee, Young Yiul Lee

01.12.2012 | PHASE I STUDIES | Ausgabe 6/2012

Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma

Jason Konner, Rachel N. Grisham, Jae Park, Owen A. O’Connor, Gillian Cropp, Robert Johnson, Alison L. Hannah, Martee L. Hensley, Paul Sabbatini, Svetlana Miranov, Samuel Danishefsky, David Hyman, David R. Spriggs, Jakob Dupont, Carol Aghajanian

01.12.2012 | PHASE I STUDIES | Ausgabe 6/2012

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

Michael Millward, Timothy Price, Amanda Townsend, Christopher Sweeney, Andrew Spencer, Shawgi Sukumaran, Angie Longenecker, Lonnie Lee, Ana Lay, Girish Sharma, Robert M. Gemmill, Harry A. Drabkin, G. Kenneth Lloyd, Saskia T. C. Neuteboom, David J. McConkey, Michael A. Palladino, Matthew A. Spear

01.12.2012 | PHASE I STUDIES | Ausgabe 6/2012

Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors

C. Massard, R. Salazar, J. P. Armand, M. Majem, E. Deutsch, M. García, A. Oaknin, E. M. Fernández-García, A. Soto, J. C. Soria

01.12.2012 | PHASE I STUDIES | Ausgabe 6/2012

First clinical pharmacokinetic dose-escalation study of sagopilone, a novel, fully synthetic epothilone, in Japanese patients with refractory solid tumors

Kazuhiro Araki, Koichi Kitagawa, Hirofumi Mukai, Toru Mukohara, Keiji Kodama, Yuichi Ando, Masaru Narabayashi, Hironobu Minami, Kiyomi Mera, Yasutsuna Sasaki

01.12.2012 | PHASE I STUDIES | Ausgabe 6/2012

Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies

Glen J. Weiss, Manuel Hidalgo, Mitesh J. Borad, Daniel Laheru, Raoul Tibes, Ramesh K. Ramanathan, Lisa Blaydorn, Gayle Jameson, Antonio Jimeno, Jeffrey D. Isaacs, Angela Scaburri, Maria Adele Pacciarini, Francesco Fiorentini, Marina Ciomei, Daniel D. Von Hoff

01.12.2012 | PHASE I STUDIES | Ausgabe 6/2012

A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study

Warren P. Mason, Mary MacNeil, Petr Kavan, Jacob Easaw, David Macdonald, Brian Thiessen, Shweta Urva, Zarnie Lwin, Lynn McIntosh, Elizabeth Eisenhauer

01.12.2012 | PHASE I STUDIES | Ausgabe 6/2012 Open Access

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors

Toshiaki Takahashi, Narikazu Boku, Haruyasu Murakami, Tateaki Naito, Asuka Tsuya, Yukiko Nakamura, Akira Ono, Nozomu Machida, Kentaro Yamazaki, Junichiro Watanabe, Ana Ruiz-Garcia, Keiji Imai, Emiko Ohki, Nobuyuki Yamamoto

01.12.2012 | PHASE I STUDIES | Ausgabe 6/2012

Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors

Pamela L. Kunz, Aiwu R. He, A. Dimitrios Colevas, Michael J. Pishvaian, Jimmy J. Hwang, Pamela L. Clemens, Marianne Messina, Remigiusz Kaleta, Fernanda Abrahao, Branimir I. Sikic, John L. Marshall

01.12.2012 | PHASE II STUDIES | Ausgabe 6/2012

A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer

In Gyu Hwang, Joung-Soon Jang, Sung Yong Oh, Suee Lee, Hyuk Chan Kwon, Gyeong Won Lee, Seil Go, Myoung Hee Kang, Young Joo Cha, Jung Hun Kang

01.12.2012 | PHASE II STUDIES | Ausgabe 6/2012

Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group

S. H. Park, M. H. Ryu, B. Y. Ryoo, S. A. Im, H. C. Kwon, S. S. Lee, S. R. Park, B. Y. Kang, Y. K. Kang

01.12.2012 | PHASE II STUDIES | Ausgabe 6/2012 Open Access

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

Thomas Yau, Hilda Wong, Pierre Chan, T. J. Yao, R. Pang, T. T. Cheung, S. T. Fan, Ronnie T. Poon

01.12.2012 | PHASE II STUDIES | Ausgabe 6/2012

Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer

Daniel Laheru, Preeti Shah, N. V. Rajeshkumar, Florencia McAllister, Gretchen Taylor, Howard Goldsweig, Dung T. Le, Ross Donehower, Antonio Jimeno, Sheila Linden, Ming Zhao, Dongweon Song, Michelle A. Rudek, Manuel Hidalgo

01.12.2012 | SHORT REPORT | Ausgabe 6/2012

Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib

Karen E. Mulder, Merrill J. Egorin, Michael B. Sawyer

01.12.2012 | SHORT REPORT | Ausgabe 6/2012

SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155

Maria Grazia di Iasio, Alessia Norcio, Elisabetta Melloni, Giorgio Zauli

01.12.2012 | SHORT REPORT | Ausgabe 6/2012

Severe meningo-radiculo-nevritis associated with ipilimumab

Flavie Bompaire, Christine Mateus, Hervé Taillia, Thierry De Greslan, Marion Lahutte, Magali Sallansonnet-Froment, Madani Ouologuem, Jean-Luc Renard, Guy Gorochov, Caroline Robert, Damien Ricard

01.12.2012 | REVIEW | Ausgabe 6/2012 Open Access

Aurora kinase inhibitors: Progress towards the clinic

Madhu Kollareddy, Daniella Zheleva, Petr Dzubak, Pathik Subhashchandra Brahmkshatriya, Martin Lepsik, Marian Hajduch

01.12.2012 | REVIEW | Ausgabe 6/2012 Open Access

Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?

Andrea Gombos, Otto Metzger-Filho, Lissandra Dal Lago, Ahmad Awada-Hussein

01.12.2012 | REVIEW | Ausgabe 6/2012

Predictive factors for response to treatment in patients with advanced renal cell carcinoma

Carolina Muriel López, Emilio Esteban, Aurora Astudillo, Pablo Pardo, Jose Pablo Berros, Marta Izquierdo, Guillermo Crespo, Paula J. Fonseca, Miguel Sanmamed, Pablo Martínez-Camblor

01.12.2012 | Erratum | Ausgabe 6/2012

Erratum to: Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma

Jason Konner, Rachel N. Grisham, Jae Park, Owen A. O’Connor, Gillian Cropp, Robert Johnson, Alison L. Hannah, Martee L. Hensley, Paul Sabbatini, Svetlana Mironov, Samuel Danishefsky, David Hyman, David R. Spriggs, Jakob Dupont, Carol Aghajanian

01.12.2012 | Erratum | Ausgabe 6/2012

Erratum to: Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy

Céline Clémenson, Cyrus Chargari, Laurent Désiré, Anne-Sophie Casagrande, Jean Bourhis, Eric Deutsch

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise